Stifel analyst Rick Wise lowered the firm’s price target on Zimmer Biomet (ZBH) to $110 from $118 and keeps a Buy rating on the shares. The firm says the company’s Q3 performance was frustratingly more mixed than it anticipated. While Zimmer did make positive progress on multiple fronts, at the same time, management highlighted that several end-of-quarter Q3 international and noncore business headwinds pressured sales by about 120bps. Stifel thinks that the quarter also illustrated Zimmer Biomet’s commercial and innovation progress, factors that are not being considered in today’s stock performance.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $112 from $122 at BTIG
- Morning Movers: Sleep Number, Pinterest plummet after earnings
- Zimmer Biomet reports Q3 adjusted EPS $1.90, consensus $1.86
- Zimmer Biomet backs FY25 adjusted EPS view $8.10-$8.30, consensus $8.14
- Zimmer Biomet price target lowered to $105 from $112 at Barclays